News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Santhera Pharmaceuticals AG Eyes Approval of Lead Drug, Catena in First Half of 2011
June 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss Santhera is aiming to seek approval for lead drug Catena to treat a rare eye disease in the first half of 2011 after a trial showed it improved sight, boosting the biotech group's prospects.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Artificial intelligence
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews
May 9, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Delays Continue as Regulator Misses Review Date for GSK’s Nucala
May 9, 2025
·
2 min read
·
Tristan Manalac
Special edition
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA
May 9, 2025
·
2 min read
·
Annalee Armstrong
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
·
5 min read
·
Angela Gabriel
